WELCOME TO The Biotechnology REPORT
Good Start Genetics
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Portal Innovations | February 03, 2022
Portal Innovations continues its momentum in Chicago by launching the second phase of its operations with the opening of 35,000 square feet of premier wet and dry lab and office space at 400 North Aberdeen in Fulton Labs. The new facility will allow Portal, a life sciences venture development engine, to grow and scale its investment in early-stage biotech companies in Chicago.
Portal has tapped Patrick Flavin to serve as President of its flagship Chicago operation. With over 20 ye...
XtalPi Inc. | November 25, 2022
XtalPi announced today that they are embarking on a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. XtalPi and CK Life Sciences will leverage their respective expertise to jointly develop a novel AI tumour vaccine R&D platform to improve the discovery and design capabilities of tumour vaccines and accelerate the development of more vaccine types. The goal of this collaboration is to realize precision treatment for patients worldwide.
MedTech, Industrial Impact
Oxford Biomedica Solutions LLC | December 15, 2022
Oxford Biomedica Solutions LLC, an AAV manufacturing and innovation company, announced today that it has signed agreements with three additional U.S. based, biotechnology companies. This places Oxford Biomedica Solutions ahead of the previously stated target of two new partners by the end of the calendar year.
Under these additional agreements, Oxford Biomedica Solutions will provide its full platform offering to support the new partners’ gene therapy programs, which cover a...
AbCellera and Atlas Venture | August 04, 2022
AbCellera and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company. The collaboration leverages Atlas’ proven track record in forming innovative biotechnology companies and AbCellera’s unique ability to quickly deliver lead drug candidates to bring transformational new medicines to patients faster.
Cell and Gene Therapy
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE